Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 6/20 | 0.79 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.51 |
| ▸ | SELE | P16581 | 5/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 7/20 | 0.49 |
| ▸ | GSK3A | P49840 | 7/20 | 0.49 |
| ▸ | GSK3B | P49841 | 7/20 | 0.49 |
| ▸ | PLK4 | O00444 | 6/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 6/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | CDK1 | P06493 | 5/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550743 | 0.88 | MAP3K8 (1.00) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5550648 | 0.88 | MAP3K8 (1.00) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5554868 | 0.87 | MAP3K8 (0.70) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5554857 | 0.87 | MAP3K8 (0.70) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5550720 | 0.87 | MAP3K8 (0.70) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5553712 | 0.87 | MAP3K8 (0.98) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5550267 | 0.86 | MAP3K8 (0.82) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5553738 | 0.85 | MAP3K8 (0.70) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| SCHEMBL5554048 | 0.85 | MAP3K8 (0.70) | MAP3K8ICAM1SELEVCAM1PIM1 | |
| Lithium Ion SCHEMBL5553717 | 0.85 | MAP3K8 (0.80) | MAP3K8ICAM1SELEVCAM1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | MAP3K8 13/4885ICAM1 4375/4885SELE 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.